As of February 7, 2025
Ethical drug
| Development code | Generic name | Stage | Indications | Formulation | Remarks <Development country> |
|---|---|---|---|---|---|
| MD-0901 | mesalazine | Filed | Ulcerative colitis （pediatric indication） |
Oral | Licensed-in from Takeda Pharmaceuticals U.S.A., Inc. In-house development <Japan> |
| FYU-981 | dotinurad | Phase III | Gout and hyperuricemia (pediatric indication) | Oral | Co-development with FUJI YAKUHIN Co., Ltd. <Japan> |
| MD-352 | dienogest formulation | Phase II/III | Dysmenorrhea | Oral | In-house development <Japan> |
| MD-712 | treprostinil | Phase II/III | Pulmonary arterial hypertension Pulmonary hypertension associated with interstitial lung disease |
Dry Powder Inhaler | Licensed-in from United Therapeutics Corporation In-house development <Japan> |
| RGB-19 | tocilizumab | Phase III | Rheumatoid Arthritis | Injection | Biosimilar Licensed-in from Gedeon Richter Plc. <Japan> |
| MND-21 | icosapent | Filed | Hypertriglyceridemia | Oral | Collaboration on development with Sumitomo Pharma (Suzhou) Co., Ltd. <China> |
Medical device
| Development code or Product name |
Stage | Intended use or indications | Remarks <Development country> |
|---|---|---|---|
| dMD-001 | Filed | Articular cartilage lesion | In-house development <Japan> |
| dMD-002 | Therapeutic confirmatory study | Cavernous nerve injury | In-house development <Japan> |
| dMD-003 | Therapeutic confirmatory study | Post-operative adhesion | In-house development <Japan> |